Feature | March 26, 2015

FDA Updates MQSA Facility Certification Extension Requirements for Digital Breast Tomosynthesis Systems

FDA, MQSA, tomosynthesis, DBT, certificate extension, requirements

March 26, 2015 — The U.S. Food and Drug Administration (FDA) released updated requirements for a mammography facility to extend its Mammography Quality Standards Act (MQSA) certification for digital breast tomosynthesis (DBT) systems.

All of the following information must be included with the application:

1: Manufacturers name of FFDM-DBT unit

2. Facility Status Information

a. Facility Name and FDA Facility ID Number
b. FDA Certificate Expiration Date
c. Current Accreditation Body for the 2D unit
d. Accreditation Expiration Date
e. Facility Contact Person for DBT unit
f. Contact Person’s Title
g. Contact Person’s Telephone, Fax, E-mail
h. Facility Address
i. Facility Owner

3. DBT Unit Identification

a. Machine Manufacturer
b. Machine Model
c. Year of Manufacture
d. Serial Number
e. Accreditation Body Unit Number

4. DBT Digital Image Receptor Identification (if interchangeable)

a. Receptor Manufacturer
b. Receptor Model
c. Year of Manufacture
d. Serial Number (if applicable)

5. Identification of Printer for Hard Copy Interpretation (mandatory even for facilities performing only soft copy interpretation)

a. Printer Manufacturer
b. Printer Model
c. Year of Manufacture
d. Serial Number

6. Final Interpretation Review Monitor Identification (if soft copy display is available)

a. Monitor Manufacturer
b. Monitor Model
c. Year of Manufacture
d. Serial Number

7. Phantom Identification

a. Phantom Manufacturer
b. Phantom Model

8. Hardcopy phantom image (3D mode) must be included when submitting application.

9. Personnel Qualifications

a. Interpreting Physicians who are qualified to interpret DBT mammograms (see Qualified Personnel)
b. Radiological Technologists who are qualified to perform DBT mammography examinations and the manufacturer recommended quality assurance tests (see Qualified Personnel)
c. Medical Physicists who are qualified to perform equipment evaluations and/or surveys of DBT mammography units (Qualified Personnel)

10. Complete Detailed report of Mammography Equipment Evaluation (MEE) (must have been conducted in accordance with 900.12(e)(10) within the 6 months prior to the request for use approval) must be included when submitting application.

a. Statement that equipment performance, as required under the following sections of the
MQSA final regulation 21 CFR 900.12(b), is met:

(1) Prohibited Equipment
(2) Specifically Designed for Mammography
(3) Motion of Tube-Image Receptor Assembly
(4)(iii) Removable Grid (if applicable to the DBT system used) (5) Beam Limitation and Light Fields
(6) Magnification
(7) Focal Spot Selection
(8) Compression
(9) Technique Factor Selection and Display
(10) Automatic Exposure Control

b. The results of quality control tests as required under the following sections of the
MQSA final regulations 21CFR 900.12(e):

(4)(iii) Compression Device Performance
(5)(i) Automatic Exposure Control Performance (if applicable to the DBT system used) (5)(ii) Kilovoltage Peak Accuracy and Reproducibility
(5)(iii) Focal Spot Condition (Resolution) (5)(iv) Beam Quality and Half-Value Layer
(5)(v) Breast Entrance Air Kerma and AEC Reproducibility (if applicable to the DBT
system used) (5)(vi) Dosimetry
(5)(vii) X-Ray Field/Light field/Image receptor/Compression paddle alignment
(5)(ix) System Artifacts
(5)(x) Radiation Output
(5)(xi) Decompression (or alternative standards allowed for these requirements) (6) Quality Control Tests – Other Modalities (Facilities must perform all DBT manufacturer recommended quality control tests including the medical physicist’s tests for Soft Copy Display system)

c. The results of the phantom image quality tests, including a sample image
d. If any of the requirements in 8 a, b, or c are not met, submit documentation of successful corrective action
e. If any of the requirements in 8 a or b are not performed, explain why the requirement is not applicable
f. Date of the MEE
g. Name and address of the physicist(s) who performed the MEE

11. DBT Manufacturer’s Quality Control Program

a. Name of the Quality Control Manual
b. Year published
c. Revision number, if not the original
d. Printing number, if not the original

12. Signature of facility contact person for the DBT unit


Note 1: Under MQSA, each manufacturer’s Digital Breast Tomosynthesis system is currently considered a separate new mammographic modality, and the personnel requirements for new modality training apply.

Note 2: In order to use the tomosynthesis portion of the unit, the facility must apply to FDA to have its certificate extended to include that portion of the unit. The certification extension only applies to the DBT portion of the unit. The facility must have the 2-D portion of the unit accredited by one of the accreditation bodies already approved to accredit the 2-D portion.

For more information: www.fda.gov

Related Content

RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...
Massachusetts Superior Court Grants Hologic Preliminary Injunction in Trade Secrets Lawsuits
News | Mammography | December 12, 2018
December 12, 2018 — A Massachusetts Superior Court granted a preliminary injunction in lawsuits by Hologic against Ch
Videos | Mammography | December 10, 2018
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, and attending radiol
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Women Benefit From Mammography Screening Beyond Age 75
News | Mammography | November 26, 2018
Women age 75 years and older should continue to get screening mammograms because of the comparatively high incidence of...
Novarad Debuts NovaMG-Pro Mammography Software at RSNA 2018
News | Mammography Reporting Software | November 25, 2018
Novarad Corp. announced new mammography software NovaMG-Pro, specifically for multimodality radiologists that read...
Volpara Solutions Showcases Latest VolparaEnterprise Software Tools at RSNA
News | Mammography | November 21, 2018
Volpara Solutions Inc. will showcase its latest artificial intelligence (AI) updates at the 104th Annual Radiological...